16
Nov
2015
Rewriting Pharma’s Broken Social Contract: Q&A with Alnylam’s John Maraganore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
13
Nov
2015
Pfizer Sizes Up Young Gun, CRISPR in the Spotlight & More Bad Behavior
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
10
Nov
2015
Pursuing a Hard Cancer Target: Q&A With Warp Drive CEO Laurence Reid
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Nov
2015
Raiding the Talent at Pfizer: Where Might The R&D Brains Go?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
6
Nov
2015
D.C. Crosshairs on Pharma, ASH Roller Coaster & An IPO Cooldown
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
2
Nov
2015
The $100M Club: See Who Makes the Cut in SF, Boston, and Beyond
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
30
Oct
2015
Pfizer’s New MegaMerger Target, Valeant Burns & Amgen’s Cancer Advance
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Oct
2015
See the Photos From the TR1000 Party in SF
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Oct
2015
Biotech Should Give More Young People a Chance
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
23
Oct
2015
Valeant’s Takedown, FDA Black Boxes & the Cancer Vaccine Scramble
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
19
Oct
2015
Playing Hardball: Academia Looks to Even the Score with VCs, Big Pharma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
Oct
2015
Theranos Exposed, Lilly Cholesterol Drug Flops & 23andMe Raises More Dough
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
14
Oct
2015
Introducing Signal: The Stat Podcast I’m Co-Hosting With Meg Tirrell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Oct
2015
Who Deserves To Be Called a Founder, and Who Doesn’t?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Oct
2015
Vertex Takes Heat, Valeant Takes Even More, and Express Scripts Cuts a Deal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Oct
2015
GlaxoSmithKline: A Bunch of Bozos, Or Crazy Like a Fox?
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
2
Oct
2015
Fallout from the Drug Pricing Fiasco, the New Thing in Genome Editing & More
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
1
Oct
2015
The Next Macro (Phage) Thing in Immuno-Oncology
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
28
Sep
2015
What Happens After The Gouging? Lock Pharma & The Payers in a Swiss Hotel
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
25
Sep
2015
The Mother of All Drug Pricing Controversies, Slingshots at FDA Nominee, and Nobel Handicapping
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share: